Volume 135, Issue 4, Pages (October 2008)

Slides:

Advertisements

Similar presentations

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

Advertisements

Volume 137, Issue 4, Pages (October 2009)

William J. Sandborn, M. D. , Christopher Gasink, M. D

The Role of Psychosocial Care in Adapting to Health Care Reform

Volume 134, Issue 7, Pages (June 2008)

Volume 126, Issue 1, Pages (January 2004)

Guillaume Bouguen, Barrett G. Levesque, Brian G

Volume 146, Issue 3, Pages e1 (March 2014)

Volume 153, Issue 3, Pages e7 (September 2017)

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab William J. Sandborn, Maria T. Abreu, Geert.

Abatacept for Crohn's Disease and Ulcerative Colitis

Volume 153, Issue 3, Pages e7 (September 2017)

Evaluation and Management of End-Stage Liver Disease in Children

Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set Christopher.

Volume 133, Issue 1, Pages (July 2007)

A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of.

Volume 154, Issue 1, Pages e6 (January 2018)

Clinical Challenges and Images in GI

Volume 134, Issue 7, Pages (June 2008)

Volume 153, Issue 1, Pages e6 (July 2017)

A Historical Perspective on Clinical Advances in Pancreatic Diseases

Volume 150, Issue 4, Pages (April 2016)

Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce A

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease Elana A. Maser, Renata Villela,

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

Volume 155, Issue 4, Pages e8 (October 2018)

Volume 130, Issue 2, Pages (February 2006)

Volume 147, Issue 3, Pages e3 (September 2014)

Volume 146, Issue 1, Pages e1 (January 2014)

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab Fernando.

Volume 132, Issue 5, Pages (May 2007)

Covering the Cover Gastroenterology

Volume 137, Issue 4, Pages (October 2009)

Volume 119, Issue 6, Pages (December 2000)

Volume 147, Issue 6, Pages e5 (December 2014)

William J. Sandborn, Stefan Schreiber, Brian G

Volume 119, Issue 6, Pages (December 2000)

Volume 146, Issue 4, Pages e2 (April 2014)

Bara Erhayiem, Rajpal Dhingsa, Christopher J

Volume 154, Issue 6, Pages (May 2018)

Volume 132, Issue 1, Pages (January 2007)

Brian G. Feagan, Gordon R. Greenberg, Gary Wild, Richard N

Covering the Cover Gastroenterology

David H. Bruining, William J. Sandborn

Volume 135, Issue 5, Pages (November 2008)

Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies

Constance E. Ruhl, James E. Everhart Gastroenterology

Ashwin N. Ananthakrishnan, David Lieberman Gastroenterology

Antoine Debourdeau, Anne Bozon, Romain Altwegg Gastroenterology

Volume 121, Issue 5, Pages (November 2001)

Volume 150, Issue 7, Pages (June 2016)

Multiple Unusual Ulcerated Skin Lesions in a Crohn's Disease Patient

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity Severine Vermeire, Stefan Schreiber,

Covering the Cover Gastroenterology

Volume 135, Issue 2, Pages (August 2008)

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study William J. Sandborn, Stefan Schreiber,

Richard J. Saad, William D. Chey Gastroenterology

Volume 151, Issue 4, Pages (October 2016)

Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Volume 126, Issue 1, Pages (January 2004)

Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease Jennifer Jones, Edward V. Loftus, Remo Panaccione,

Walter Reinisch, Jean-Frederic Colombel, William J

Volume 117, Issue 4, Pages (October 1999)

Volume 117, Issue 3, Pages (September 1999)

Volume 142, Issue 2, Pages e3 (February 2012)

Issue Highlights Clinical Gastroenterology and Hepatology

Matthew J. Lee, Claire E. Parker, Sarah R

Medical Therapy for Refractory Pediatric Crohn’s Disease

The Role of Psychosocial Care in Adapting to Health Care Reform

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis Jean-Frédéric Colombel,

Presentation transcript:

Volume 135, Issue 4, Pages 1130-1141 (October 2008) A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease William J. Sandborn, Brian G. Feagan, Richard N. Fedorak, Ellen Scherl, Mark R. Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts Gastroenterology Volume 135, Issue 4, Pages 1130-1141 (October 2008) DOI: 10.1053/j.gastro.2008.07.014 Copyright © 2008 AGA Institute Terms and Conditions

Figure 1 Efficacy and safety evaluations included 104 patients in population 1 and 27 patients in population 2. Gastroenterology 2008 135, 1130-1141DOI: (10.1053/j.gastro.2008.07.014) Copyright © 2008 AGA Institute Terms and Conditions

Figure 2 Efficacy of ustekinumab. (A) Clinical response over time in the combined ustekinumab and placebo groups in population 1. (B) Clinical response over time in the combined ustekinumab and placebo groups in Population 1 who previously had been treated with infliximab. (C) Odds ratio and 95% confidence intervals for comparing the proportion of patients in clinical response at week 8 in the combined ustekinumab or placebo groups in population 1 stratified by baseline weight, disease characteristics, and Crohn's disease medication history. (D) Median C-reactive protein (CRP) concentrations at week 0 and week 8 in patients treated with subcutaneous or intravenous ustekinumab or placebo in population 1. Gastroenterology 2008 135, 1130-1141DOI: (10.1053/j.gastro.2008.07.014) Copyright © 2008 AGA Institute Terms and Conditions